A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection by K. Yeon Choi et al.
A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant
Vaccine Strategy Is Effective in Reducing Congenital Infection
K. Yeon Choi, Matthew Root, Alistair McGregor
Department of Microbial Pathogenesis and Immunology, Texas A&M University, Health Science Center, College of Medicine, College Station, Texas, USA
ABSTRACT
Congenital cytomegalovirus (CMV) infection is a leading cause of mental retardation and deafness in newborns. The guinea pig
is the only small animal model for congenital CMV infection. A novel CMV vaccine was investigated as an intervention strategy
against congenital guinea pig cytomegalovirus (GPCMV) infection. In this disabled infectious single-cycle (DISC) vaccine strat-
egy, a GPCMVmutant virus was used that lacked the ability to express an essential capsid gene (theUL85 homologGP85) except
when grown on a complementing cell line. In vaccinated animals, the GP85mutant virus (GP85 DISC) induced an antibody re-
sponse to important glycoprotein complexes considered neutralizing target antigens (gB, gH/gL/gO, and gM/gN). The vaccine
also generated a T cell response to the pp65 homolog (GP83), determined via a newly established guinea pig gamma interferon
enzyme-linked immunosorbent spot assay. In a congenital infection protection study, GP85 DISC-vaccinated animals and a
nonvaccinated control group were challenged during pregnancy with wild-type GPCMV (105 PFU). The pregnant animals car-
ried the pups to term, and viral loads in target organs of pups were analyzed. Based on live pup births in the vaccinated and con-
trol groups (94.1% versus 63.6%), the vaccine was successful in reducing mortality (P 0.0002). Additionally, pups from the
vaccinated group had reduced CMV transmission, with 23.5% infected target organs versus 75.9% in the control group. Overall,
these preliminary studies indicate that a DISC CMV vaccine strategy has the ability to induce an immune response similar to
that of natural virus infection but has the increased safety of a non-replication-competent virus, which makes this approach at-
tractive as a CMV vaccine strategy.
IMPORTANCE
Congenital CMV infection is a leading cause of mental retardation and deafness in newborns. An effective vaccine against CMV
remains an elusive goal despite over 50 years of CMV research. The guinea pig, with a placenta structure similar to that in hu-
mans, is the only small animal model for congenital CMV infection and recapitulates disease symptoms (e.g., deafness) in new-
born pups. In this report, a novel vaccine strategy against congenital guinea pig cytomegalovirus (GPCMV) infection was devel-
oped, characterized, and tested for efficacy. This disabled infectious single-cycle (DISC) vaccine strategy induced a neutralizing
antibody or a T cell response to important target antigens. In a congenital infection protection study, animals were protected
against CMV in comparison to the nonvaccinated group (52% reduction of transmission). This novel vaccine was more effective
than previously tested gB-based vaccines andmost other strategies involving live virus vaccines. Overall, the DISC vaccine is a
safe and promising approach against congenital CMV infection.
Human cytomegalovirus (HCMV), a betaherpesvirus, hasevolved very closely with its human host. Virus infection in a
healthy host is normally asymptomatic but leads to a lifelong in-
fection. In contrast, infection of an immunocompromised host
(AIDS and transplant patients) or virus reactivation because of an
impaired immune system can have severe consequences of mor-
bidity and mortality, but established antiviral therapy can poten-
tially reduce the impact of the disease in these patients (1). An-
other important aspect of cytomegalovirus disease is congenital
infection, where the virus crosses the placenta and infects the fetus
in utero. This occurs in approximately 2% of live births in the
United States and can lead to serious symptomatic disease, includ-
ing impaired vision, mental retardation, and sensorineural hear-
ing loss (SNHL) in newborns (2–6). Established antiviral therapy
cannot be used because of possible teratogenic and toxic side ef-
fects associated with transmission of the drugs to the fetus in utero
(1). However, long-term (6-month) valganciclovir antiviral ther-
apy is now recommended for infants with central nervous system
(CNS) involvement to improve SNHL and development outcome
(7). Importantly, the greatest risk of congenital infection is for
mothers who acquire a primary infection during pregnancy; prior
immunity can reduce the risk by up to 69% (8). Hence, the impact
of a vaccine is potentially substantial, especially in the United
States, European Union, and Japan, where up to 50% of women of
child-bearing age are negative for HCMV (9–11) and therefore at
a greater risk of primary infection during pregnancy.
Any proposed intervention for the prevention or treatment of
HCMV infection should ideally be evaluated in a preclinical
model. Unfortunately, HCMV is extremely species specific. Con-
sequently, animal model pathogenicity, vaccine, and antiviral
studies are carried out using animal-specific CMVs (12–16). The
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guinea pig is unique insofar as it is the only small animal model
that allows the study of congenital CMV infection, unlike the
mouse or rat model (17). Both human and guinea pig placentas
are hemomonochorial, containing a homogenous layer of tropho-
blast cells separating maternal and fetal circulation (18–20). Ad-
ditionally, as with human pregnancy, the guinea pig gestation pe-
riod (approximately 65 days) can be divided into trimesters.
Importantly, guinea pig CMV (GPCMV) congenital infection
causes disease in the fetus and in newborn pups similar to that
found in humans, including SNHL (21–23). Consequently, the
guinea pig model is well suited for testing of intervention strate-
gies aimed at preventing congenital CMV infection (1, 24, 25).
A major drawback in GPCMV research has largely been over-
come by the recent sequencing of the viral genome and the devel-
opment of infectious bacterial artificial chromosome (BAC)
clones of GPCMV (15, 26–29). Manipulation of an infectious
GPCMV BAC has allowed the preliminary study of some viral
genes (1, 30–36). Analysis of the viral genome (15, 29) indicated
that GPCMV encodes homologs to the HCMV glycoproteins (gB,
gH, gL, gM, gN, and gO) in genes colinear with the HCMV ge-
nome (designated GP55, GP75, GP115, GP100, GP73, and GP74,
respectively). In HCMV, these six glycoproteins (gB, gH, gL, gM,
gN, and gO) are required for fibroblast cell entry, and they form
the glycoprotein complexes gCI (gB), gCII (gM/gN), and gcIII
(gH/gL/gO) on the viral membrane (37–39). In HCMV, these
complexes are important neutralizing antibody targets and vac-
cine candidates (40–44). We recently demonstrated that GPCMV
forms functionally similar glycoprotein complexes, and these
complexes are essential for infection of fibroblast cells as well as
serving as important target antigens (36). Additionally, GPCMV
forms a homologous pentameric complex (gH/gL/UL128-131)
that is necessary for epithelial tropism in HCMV (45) and
GPCMV (103) as well as other cell types (46).
In both HCMV and GPCMV, the viral glycoprotein gB is the
immunodominant neutralizing viral antigen (47–51). A recombi-
nant HCMV gB has been investigated as a candidate subunit vac-
cine in phase 2 clinical trials, but this vaccine provides at best
approximately 50% efficacy (41). This is despite high antibody
titers which are effective in neutralizing virus on fibroblasts (41,
52). Importantly, separate studies of serum from gB-vaccinated
individuals showed that it was less effective at neutralizing virus
infection on endothelial and epithelial cells, in comparison to con-
valescent-phase sera from HCMV-infected individuals (53–55).
This demonstrated the importance of other viral neutralizing tar-
get antigens for infection on these cell types. Consequently, other
target antigens should be considered important in the develop-
ment of a vaccine against congenital CMV infection. The impor-
tance of other target antigens can be demonstrated in the guinea
pig model, where a gB vaccine, despite high antibody titers, fails to
fully protect against congenital CMV infection (51, 56, 57). The
gH/gL complex has been identified as a potentially important tar-
get antigen, including in a congenital GPCMV infection model. In
this study, a novel antibody therapy strategy was found to be ef-
fective in reducing the incidence of congenital CMV infection (36,
58). Consequently, an effective immune response to both gB and
gH/gL is likely an important factor for a successful vaccine against
congenital CMV.
Although patients in the convalescent phase of HCMV infec-
tion have an antibody response to various important neutralizing
antigens, they also have a heightened immune response to the
major tegument protein pp65, which is considered the major T
cell target antigen (59). The pp65 antigen has been explored as a T
cell vaccine target in animal models and in clinical trials (60).
GPCMV encodes a homolog to pp65 (30), and a pp65 homolog
(GP83) vaccine strategy based on a defective alphavirus delivery
approach resulted in partial protection against congenital GPCMV
infection, indicating the potential importance of a T cell-mediated
immune response against congenital infection (61). However,
HCMV also encodes other T cell target antigens (immediate-early
protein 1 [IE1, IE2, pp150, and gB) which are also likely important
for the generation of a protective T cell immune response against
HCMV and also most likely against congenital CMV infection
(62). Importantly, GPCMV encodes homologs to these proteins.
Undoubtedly, development of a successful vaccine strategy
against congenital CMV may require an approach that induces an
immune response to multiple target antigens, including both
those that generate antibody responses and those that generate a T
cell response and thus mimic a natural CMV infection, to induce
long-term protection.
Potentially, one of the most effective vaccine strategies would
be to use an attenuated virus, as it would mimic a natural infec-
tion. However, a live attenuated virus may have the potential to
establish latency in the host and therefore could be considered a
high-risk vaccine strategy. An alternative is the use of a non-rep-
lication-competent virus, which infects cells in a manner similar
to a wild-type virus and expresses an array of viral antigens but is
incapable of producing progeny virus because of knockout of a
specific essential gene. The GPCMV vaccine strategy described in
this study was based on a targeted knockout of a capsid gene which
is essential for virus assembly but relatively unimportant as a vac-
cine target. Importantly, CMV capsid genes are highly conserved
between HCMV and animal CMV. The process of capsid assembly
in HCMV has been well studied and defined (63). The defective
infectious single-cycle (DISC) vaccine strategy was based on a
UL85 homolog (GP85) mutant that encodes the minor capsid
protein, which dimerizes with itself and the minor capsid binding
protein (UL46) to form a triplex as part of a fundamental building
block for capsid assembly (63). The GP85 capsid gene was placed
under the control of the Tet-Off Advanced transactivation system
(Clontech) (64) in a GPCMV BAC, and mutant virus was propa-
gated on a newly developed Tet-Off Advanced guinea pig fibro-
blast cell line. Animals vaccinated with the GP85 DISC GPCMV
showed an immune response to important antibody target anti-
gens (gB, gH/gL, and gM/gN). Additionally, DISC-vaccinated an-
imals showed a T cell response to the pp65 homolog (GP83),
which was evaluated in a novel gamma interferon (IFN-) en-
zyme-linked immunosorbent spot (ELISPOT) assay. Finally, in a
congenital infection vaccine protection study, GP85 DISC-vacci-
nated animals demonstrated a highly protective immune response
against congenital infection compared to a nonvaccinated control
group. Overall, the GPCMV DISC vaccine strategy is a highly
promising intervention strategy against congenital infection.
MATERIALS AND METHODS
Cells, viruses, and oligonucleotides. GPCMV (strain 22122, ATCC
VR682) and first-generation GPCMV BAC-derived viruses (26, 27) were
propagated on guinea pig fibroblast lung cells (GPL; ATCC CCL 158) or
Tet-Off GPL cells (see below) in F-12 medium supplemented with 10%
fetal calf serum (FCS; Life Technologies), 10,000 IU of penicillin/liter, 10
mg of streptomycin/liter (Life Technologies), and 7.5% NaHCO3 (Life
Guinea Pig Cytomegalovirus DISC Vaccine
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Technologies) at 37°C, 5% CO2. Virus titrations were carried out on
six-well plates. Plaques were stained with 10% Giemsa stain or visual-
ized by fluorescence microscopy. High-titer virus stocks were gener-
ated as previously described (36). Pathogenic wild-type GPCMV used
in congenital CMV challenge studies was serially maintained as sali-
vary gland stocks from infected guinea pigs. All oligonucleotides were
synthesized by Sigma-Genosys (The Woodlands, TX) and are listed in
Table 1.
Tet-Off Advanced GPL cell line. In order to generate a Tet-Off Ad-
vanced GPL cell line, GPL cells in 6-well plates were transfected with
pTet-Off Advanced plasmid (4g/well; Clontech Laboratories), and cells
were maintained under neomycin, G418 (Life Technologies), and antibi-
otic (400 to 600 g/ml) selection in complete F-12 medium as described
above. Selection medium was changed every third day. Individual colo-
nies of cells were identified and clonally isolated by cloning rings and
seeding into separate T-25 flasks and expanded under G418 selection (400
g/ml) as separate cell lines. Thirty individual cell lines were generated,
and frozen low-pass stocks were maintained in liquid nitrogen following a
standard protocol. G418-resistant GPL cell lines were screened for expres-
sion of the tTA2 transactivator (Clontech Laboratories) based on the abil-
ity of the cell line to enable expression of a luciferase reporter gene placed
under pTREtight promoter control in a recombinant expression plasmid,
pTREtightLUC (Clontech Laboratories). Results of a transactivation/ex-
pression assay for luciferase expression were analyzed by bioluminescence
imaging of the plasmid-transfected wells. GPL or presumptive GPL Tet-
Off (tTA-positive) cells in separate 6-well dishes were transfected with
pTRELuc plasmid (2 g/well; Clontech Laboratories) following a stan-
dard transfection protocol (36). At 24 h postexpression, the medium in
the wells was replaced with fresh F-12 complete medium (without G418).
D-luciferin substrate (100 g/ml; Promega) was also added to the trans-
fected wells and incubated at 37°C. At 15 min postincubation, the plates
were imaged (IVIS 50; Xenogen) (35) for 5 min. Control GPL cells in
6-well plates and transfected with pTREtightLuc were also imaged. As a
positive control for bioluminescence imaging, separate GPL cells in six-
well dishes were transfected with a second luciferase expression plasmid,
pcDNA3-Luc (A. McGregor, unpublished data). This plasmid harbors the
luciferase reporter cassette under HCMV IE promoter control on the
backbone of a pcDNA3.0 plasmid (Life Technologies). The pcDNA3-Luc
construct provided the maximal level of luciferase expression/biolumi-
nescence on both GPL and Tet-Off GPL cell lines and was not dependent
upon tTa2 transactivation for expression. On pTREtightLuc-transfected
cells, bioluminescent signal was only detected on cells expressing tTA2
(Tet-Off Advanced transactivator).
Cloning ofGPCMVgenes and generation ofGP85 locus shuttle vec-
tors. The GPCMV sequence was based on the complete 22122 viral ge-
nome sequence (GenBank accession AB592928.1). Our methods for gen-
eration of individual shuttle vectors for specific gene knockout and
construction of transient-expression vectors are described in more detail
below. For generation of GP85 5= untranslated region (UTR) mutants, an
initial construct was generated with flanking sequences (GP85 and GP86
coding sequences) for recombination to enable deletion of the original
GP85 5= UTR sequence and substitution of specific sequences. The tar-
geted deletion (Fig. 1) removed all of the intergenic noncoding sequences
between the GP85 and GP86 open reading frame (ORF) except for 3 bases
prior to the GP85 ATG start and 4 bases after the stop codon of GP86
(deletion GPCMV coordinates [bases] 135907 to 136179). The left GP85-
flanking sequence was PCR amplified with primers FEcGP85FLK and
RBmGP85FLK, and the 0.9-kb sequence (GPCMV coordinates 134992 to
135906) was cloned as an EcoRI/BamHI fragment into pUC19 to generate
pGP85FLK. The right GP86-flanking sequence was PCR amplified with
primers FBmGP86FLK and RHdGP86FLK, and the 0.5-kb sequence
(GPCMV coordinates 136180 to 136681) was cloned as a BamHI/HindIII
fragment into pUC19 to generate pGP86FLK. Both constructs were se-
quenced to verify the GPCMV sequence (data not shown). Next, the
GP86FLK cassette was isolated from pGP86FLK as a BamHI/HindIII frag-
ment and cloned into pGP85FLK cut with BamHI/HindIII to generate a
construct carrying both left- and right-flanking recombination arms sep-
arated by a BamHI site. The modified construct was designated pGP85/
GP86. Next, a kanamycin (Km) cassette from pACYC177 (NEB) (36) was
PCR amplified with primers FBgXhBmKm and RBgEcVSlKm. The 1.1-kb
PCR product was isolated by agarose gel electrophoresis, digested with
BglII, and cloned into pGP85/GP86 cut with BamHI. The correct orien-
tation of the construct carried the Km cassette running in the opposite
direction to the GP85 and GP86 genes and was designated pGP8586Km
(data not shown). Next, the simian virus 40 (SV40) poly(A) sequence
from peGFP-C1 (Clontech Laboratories) was PCR amplified with the
primers FSV40AEcSl and RSV40AEcSl. The 330-bp fragment had novel
EcoRI and SalI sites introduced into both the 5= and 3= ends and was
cloned initially into pNEB193 (NEB) cut with EcoRI to generate
pNEBSV40polyA. The SV40 poly(A) portion was next isolated as a SalI
fragment from pNEBSV40polyA and cloned into pGP8586Km cut with
SalI, which introduced the SV40 poly(A) sequence downstream of the
GP86 stop codon in a plasmid designated pGP8586SV40AKm. Next,
the TREtight promoter was PCR amplified as a BamHI fragment from
pTREtight (Clontech Laboratories) and cloned initially into pNEB193
(NEB) to generate pNEBTRE, and the promoter sequence was verified
(data not shown). The TREtight promoter as a BamHI fragment was then
isolated and cloned into pGP8586SV40AKm cut with BamHI, and its
orientation was determined by XhoI digestion. The correct construct
placed the pTREtight promoter directly upstream of the GP85 coding
sequence. This construct, which was used to generate the DISC virus
strain, was designated pGP8586TRESV40AKm. The cloning strategy for
the shuttle vectors is summarized in Fig. 2. In order to further dem-
onstrate the essential nature of the GP85 protein, an additional GP85-
knockout shuttle vector was generated synthetically (via DNA2.0),
which deleted the majority of the GP85 coding sequence of pSYDGP85
(codons 58 to 241 deleted). This shuttle vector was further modified by
the insertion of a Km BamHI cassette (36) to enable selection of the
GPCMV GP85 knockout mutant BAC. The GP85 deletion knockout
vector was designated pSYDGP85Km.
TABLE 1 Oligonucleotides
Oligonucleotide Sequence
FEcGP85FLK 5=GATAGAGAATTCGTTAAACTCAGCCTTTGAAGATACAAGTAGCTGATTTGTTGTC
RBmGP85FLK 5=CAGACATGGATCCGACATGGAGACCACGACGTTCTGCACCTTCG
FBmGP86FLK 5=TAGAGTCGGATCCGAGATCAGAGCGAGTTAAATAAAATACTGTCCTGGAG
RHdGP86FLK 5=GAGATAGCAAGCTTGTTTAAACTACGACGACGAGGCCGCGCGCCGCATGCTCTATAACCAC
FBgXhBmKm 5=AGATAGAAGATCTCTCGAGGATCCGATTTATTCAACAAAGCCACG
RBgEcVSlKm 5=AGCATGAAGATCTGATATCGTCGACGCCAGTGTTACAACCAATTAACC
FSV40AEcSl 5=ATAGATAGAATTCGTCGACTTAATTAATCTCTAGAGGATCATAATCAGCCATACCACATTTGTAG
RSV40AEcSl 5=AGATAGAGAATTCGTCGACGATATCGCAGTGAAAAAAATGCTTTATTTGTGAAATTTG
FTREBm 5=ATAGATAGGATCCTCGAGTTTACTCCCTATCAGTGATAG
RTREBm 5=AAGATAGGATCCAGGCGATCTGACGGTTCACTAAACGAGC
Choi et al.
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Generation of mutant GPCMV BACmids and analysis of GPCMV
BAC mutants. An inducible ET recombination system (Gene Bridges)
was introduced into DH10B bacterial cells containing a first-generation
GPCMV BAC plasmid (26, 27), and mutagenesis of the GPCMV BAC was
performed using linearized shuttle vectors encoding a kanamycin marker
as previously described (32). Isolated mutant GPCMV BAC colonies were
characterized by separate EcoRI and HindIII restriction digestions of BAC
DNA to verify the accuracy of the predicted genome configuration after
mutation (26, 27). Insertion of the Km drug resistance cassette into the
viral genome introduced a novel HindIII restriction enzyme site at the site
of mutation to enable verification of locus modification. Specific gene
modifications were confirmed by comparative PCR analysis between
wild-type and mutant GPCMV BACs using common flanking primers for
each gene (Table 1). PCRs were carried out under conditions described by
McGregor et al. (32), except the extension time at 72°C was modified
based on the size of each gene (based on 30 s of extension per 500 bases).
The gene knockout for mutants was further verified by sequencing of the
cloned PCR product.
Generation of mutant GPCMV. For generation of recombinant vi-
ruses, large-scale GPCMV BAC DNA was purified from E. coli strain
DH10B by using a maxiplasmid kit (Qiagen). BAC DNA was transfected
onto GPL or GPL Tet-Off cells in six-well dishes by using Lipofectamine
2000 (Invitrogen) as previously described (33). GPCMV BAC transfec-
tions were carried out with two independent clones for each gene knock-
out/modification. Transfections were followed for at least 4 weeks for the
production of viral plaques. Green fluorescent protein (GFP)-positive
viral plaques were detected via microscopy (33). Noninfectious mutants
produced only single GFP-positive cells that did not progress to viral
plaques. GPCMV mutant BAC transfections were carried out multiple
times (minimum of 6 times) for each clone. Rescue of lethal knockout
mutants was by cotransfection of the mutant GPCMV BAC DNA with
a 1.7-kb PCR product of the wild-type GP85/GP86 locus generated
from wild-type GPCMV BAC DNA with primers FEcGP85FLK and
RHdGP86FLK (Table 1).
Ethics. Guinea pig (Hartley) animal studies were carried out under
IACUC guidelines (Texas A&M University or University of Minnesota).
All study procedures were carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health and published by the National Research
Council (65). Animals were observed daily by trained animal care staff,
and animals that required care were referred to the attending veterinarian
for immediate care or euthanasia. Terminal euthanasia was carried out by
lethal CO2 overdose followed by cervical dislocation in accordance with
IACUC protocols and NIH guidelines. Animals purchased from Charles
River Laboratories were verified seronegative for GPCMV by toe nail clip
bleed and anti-GPCMV ELISA analysis of serum samples as previously
described (36). Animal studies were carried out to determine the fol-
lowing: (i) the immune (antibody) response to the GPCMV DISC
vaccine; (ii) the T cell immune response to the GPCMV pp65 homolog
protein; (iii) the level of protection against congenital GPCMV infection
provided by the DISC vaccine. Initial DISC vaccine regimen studies were
carried as described below in Results. Congenital GPCMV protection
studies were carried out (described below). Additionally, animals hyper-
immune to wild-type GPCMV were evaluated for the antibody response
to GPCMV and specific glycoprotein complexes via ELISA, and neutral-
izing antibody titers were also determined. Guinea pigs (n 5) were made
FIG 1 Nucleotide sequence of the GP85/GP86 locus. The sense genome strand sequence is shown. Both GP85 and GP86 are encoded on the complementary
strand. The sequence used for flanking arms in shuttle vector (Fig. 2) recombination are highlighted. The GP85 flanking sequence includes GPCMV bases 134992
to 135906; GP86 flanking sequence includes bases 136180 to 136681; the deleted intergenic sequence includes bases 135907 to 136179.
Guinea Pig Cytomegalovirus DISC Vaccine
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hyperimmune to GPCMV by three injections of wild-type GPCMV via
the subcutaneous route (105 PFU per injection). Each injection was sep-
arated by an interval of 4 weeks. Animals were evaluated after the first and
last injections for anti-GPCMV titer. Animals were euthanized at approx-
imately 4 weeks after the last injection, and sera were pooled for evaluation
of antibody titers (anti-GPCMV, anti-gB, anti gH/gL, and anti-gM/gN).
Additionally, splenocytes from individual animals were used to evaluate
the T cell response to GP83 via gamma interferon ELISPOT assay as de-
scribed above.
Congenital GPCMV vaccine protection studies. Seronegative female
guinea pigs were randomly assigned to two different groups. Group 1
(DISM; n  14) was vaccinated subcutaneously with the GPCMV DISC
vaccine (1  103 PFU) and boosted with a second inoculation 1 month
later with a repeat dose (1 103 PFU). Animals were confirmed serocon-
verted for GPCMV and paired with seronegative males for mating. Dams
were confirmed pregnant by palpitation at approximately day 20 to 25 of
gestation. A second control group of nonvaccinated seronegative females
(NOD; group 2; n  15) was also paired for mating. At late second tri-
mester/early third trimester, pregnant animals in both groups were chal-
lenged with the salivary gland stock of wild-type GPCMV (105 PFU) via
subcutaneous inoculation, and animals were allowed to go to term. The
viral loads in target organs (liver, lung, spleen, brain) of live and stillborn
pups were evaluated by real-time PCR.
Real-time PCR.Tissues were collected from euthanized guinea pigs to
determine viral loads. For pups from congenital infection studies, tissues
(lung, liver, spleen, brain) were collected within 3 days postbirth. Pup-
specific placenta was collected and preserved for DNA extraction when
applicable. For tissue DNA extraction, FastPrep 24 (MP Biomedical) was
used to homogenize tissues as a 20% (wt/vol) homogenate in lysing matrix
D (MP Biomedicals). DNA was extracted using the QIAxtractor apparatus
(Qiagen) according to the manufacturer’s tissue protocol instructions.
Viral load was determined by real-time PCR on a LightCycler 480 system
(Roche Applied Science). Primers and hydrolysis probe were designed
using the LightCycler Probe Design2 program to amplify a product from
the GPCMV GP44 gene: forward primer, 5=TCTCCACGGTGAAAGAGT
TGT; reverse primer, 5=GTGCTGTCGGACCACGATA; hydrolysis probe,
5=– 6-carboxyfluorescein–TCTTGCTCTGCAGGTGGACGA– black hole
quencher 1. The PCR mixture contained LightCycler probes master mix
(Roche Life Sciences), 0.4 M primers and 0.1 M probe, 0.4 U uracil
N-glycosylase (UNG) in a 25-l total reaction volume, including 10 l of
DNA per reaction mixture. Standard controls and no-template controls
(NTC) were run with each assay for quantification. LightCycler 480 am-
plification parameters were as follows: UNG step for 10 min at 40°C,
followed by activation at 95°C for 10 min, then 45 cycles of denaturation
at 95°C for 15 s, annealing at 56°C for 15 s, and elongation at 72°C for 10
s. Data were collected by “single” acquisition during the extension step.
Data were analyzed with the LightCycler data analysis software (version
1.5.1; Roche). A standard curve was generated using serial dilutions of
GPCMV GP44 plasmid (33) at known concentrations for quantification
and determination of assay sensitivity. The sensitivity of the assay was
determined to be 5 copies/reaction mixture. Viral loads are expressed as
the copy number per milligram of tissue. Results were calculated as the
mean values of triplicate PCR runs per sample.
ELISAs, GPCMV neutralization assays, and Western analysis. An
anti-GPCMV ELISA and specific glycoprotein complex ELISAs (anti-gB,
anti-gH/gL, and anti-gM/gN) were carried out as previously described
(36). MaxiSorp ELISA plates (Nunc) were coated with 0.25 g of either
Ag or Ag preparations diluted in carbonate coating buffer overnight at
4°C, washed in phosphate-buffered saline (PBS) with Tween 20, and then
blocked with 2% nonfat dry milk. Test sera were diluted in blocking buffer
in doubling dilutions from 1:80 to 1:5,120, incubated for 2 h at 37°C, and
then reacted with anti-guinea pig IgG– horseradish peroxidase (HRP)-
conjugated antibody (Sigma) diluted (1:1,000) in blocking buffer for an
additional 1 h at 37°C before reacting with tetramethylbenzidine mem-
brane peroxidase substrate (KPL). The net optical density at 450 nm
(OD450) was attained by subtracting the OD of Ag
 preparations from the
FIG 2 Cloning strategy for generation of a shuttle vector encoding GP85 under Tet-Off (TRE-tight) promoter control. (Steps 1 and 2) Parts of the GP85 (5=) and
GP86 (3=) coding sequences were separately cloned via PCR into pUC19 to generate pGP85FLK and pGP86FLK. (Step 3) The GP86 coding sequence was then
cloned into pGP85FLK as a BamHI/HindIII fragment to generate pGP85GP86, which lacked the intergenic sequence between GP85 and GP86. (Steps 4 to 6) A
BglII Km cassette was introduced to generate pGP8586Km (steps 4 and 5), which was digested with SalI to enable cloning of a SV40 poly(A) cassette to generate
pGP8586SV40AKm (step 6). (Step 7) The TREtight promoter from pTREtight (Clontech) was PCR cloned as a BamHI fragment immediately upstream of the
GP85 coding sequence to generate pGP8586TRESV40AKm. Shuttle vectors (steps 5, 6, and 7) linearized with PmeI were used to modify the GP85/GP86
intergenic locus in the GPCMV BAC via homologous recombination in separate reactions to introduce the modified sequence, as described in Materials and
Methods, to generate the DISC GPCMV BAC and other BAC mutants.
Choi et al.
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OD of Ag preparations. ELISA reactivity was considered positive if the
net OD was greater than or equal to 0.2 for GPCMV-negative serum.
GPCMV neutralization assays were performed on GPL fibroblast cells
with a GFP-tagged GPCMV (vAM403) (26), and neutralization assays
were performed as previously described (36). The final neutralizing anti-
body titer was the highest dilution producing a 50% or greater reduction
in plaques compared to the virus-only control. Western blot assays were
carried out as previously described (36) using wild-type virus-infected cell
lysate or sucrose-purified virions plus control mock-infected GPL cell
lysate. Sera from vaccinated animals from treatment regimen 1 (R1;
1:2,000 dilution) were used in conjunction with anti-guinea pig IgG–HRP
conjugate (1:500 dilution; Sigma).
Guinea pig IFN- ELISPOT assay. Anti-guinea pig IFN-monoclo-
nal antibodies used in the assay were based on previously characterized
monoclonal antibodies against guinea pig IFN- (66, 67). Hybridoma cell
lines for the production of the monoclonal antibodies were a generous gift
from H. Schäfer, Robert Koch-Institute, Germany. Large-scale antibody
production and purification were carried out by Genscript. IFN-
ELISPOT assays were performed in polyvinylidene difluoride membrane
96-well plates. Membranes were presoaked with 70% ethanol, then
washed with 1 PBS to thoroughly remove the alcohol prior to coating
with 0.5 g guinea pig IFN- capture antibody (V-E4), and incubated
overnight at 4°C. Membranes were washed with 1PBS and then blocked
with RPMI plus 10% FCS for 2 h at room temperature. Splenocytes were
prepared as previously described (68). Briefly, isolated spleens harvested
from euthanized animals were immediately homogenized in PBS, homog-
enates were put through a 70-m cell strainer, and red blood cells were
lysed. Splenocytes were washed with 1 PBS three times before being
resuspended in RPMI medium containing 10% FBS and antibiotic/anti-
mycotic. Cells were counted via trypan blue exclusion, and 1  105 cells
were used per well. Blocked membranes were washed once with PBS be-
fore splenocytes were added. GPCMV GP83 peptide pools (see below)
were added to each well of cells at a final concentration of 5 g/ml. Con-
canavalin A (ConA; 10 g/ml) was used as a positive control, and other
controls included cell-only controls, a dimethyl sulfoxide (DMSO) con-
trol (peptide background), GFP (nonspecific peptide control), and medi-
um-only control. Plates were covered with foil and then incubated at 37°C
in a 5% CO2 cell culture incubator for 18 h. Membranes were washed with
wash buffer (1 PBS plus 0.1% Tween 20) 5 times before a detection
antibody, biotinylated N-G3, was added and mixtures were incubated at
room temperature for 2 h. Detection antibody was diluted to 1g/ml with
diluent (1 PBS, 1% bovine serum albumin, 0.05% Tween 20), and the
mixture was filtered through a 0.2-m filter before use. Membranes were
washed with wash buffer 3 times before 100 l of streptavidin-alkaline
phosphatase (R&D Systems), diluted 1:3,200 in diluent, was added and
the mixture was incubated for 1.5 h at room temperature. A 100-l vol-
ume of 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium
(Life Technologies) was added to membranes, which were then washed 3
times in wash buffer before incubation for 30 min at room temperature,
protected from light. Membranes were washed 2 times in distilled water,
inverted onto blots, and dried before counting the spots on an Immuno-
Spot S6 analyzer (CTL). Final counts were calculated based on the number
of spot-forming cells (SFC) per 106 cells, after subtraction of the number
of background spots (cells only, without any stimulation).
A total of 140 PEPscreen 9-amino-acid peptides overlapping by 5
amino acids were generated (Sigma-Aldrich, The Woodlands, TX) to cre-
ate the GPCMV GP83 peptide library, expanding the full-length gene.
Nine-amino-acid peptides were used to target CD8 T cell activation
(69). Each peptide was reconstituted to 10 mg/ml with DMSO. Peptide
pools were generated using a configuration matrix previously described
(69, 70). The GP83 matrix consisted of 24 peptide pools in a 12-by-12 grid,
with each pool containing 12 peptides. Pools IX, X, XI, and XII contained
11 peptides, and pool XXIV had 8 peptides. Additional DMSO was added
to keep the concentration the same in all pools. All peptide pools were
diluted to a 10-g/ml working stock in RPMI for stimulation. The matrix
was designed for each peptide to be included in exactly 2 pools, keeping
the number of pools at a minimum. The intersection of positive pools
corresponded to the stimulating peptides.
Statistical analysis. Mean antibody titers (ELISA and neutralizing an-
tibody tests) in the vaccine study and hyperimmune GPCMV-infected
animals were compared with the Mann-Whitney test. In congenital infec-
tion studies, pup outcome and transmission rates were compared by using
Fisher’s exact test. GPCMV viral loads in specific target organs of pups
were compared with the Student t test or/and Mann-Whitney test, de-
pending on sample size. All comparisons were two-tailed tests.
RESULTS
Generation of a GPCMVDISC virus strain. A lethal gene knock-
out was engineered into the GPCMV genome to render the virus
incapable of productive infection unless the mutant virus was
grown on a complementing cell line. This mutant virus was the
basis of the GPCMV vaccine strategy and is referred to as a DISC
(defective infectious single-cycle) virus vaccine. This terminology
was originally developed for a herpes simplex virus (HSV) vaccine
strategy, which was based on a glycoprotein (gH) knockout virus
(71). The GPCMV DISC vaccine strategy was based on a targeted
knockout of a capsid gene, as the gH glycoprotein was considered
potentially important for glycoprotein complex formation and
consequently an important target antigen(s). In contrast, the viral
capsid genes are essential for virus assembly but in themselves are
relatively unimportant vaccine targets. Additionally, a capsid mu-
tant was considered unlikely to interfere with expression of other
viral proteins or the assembly of viral glycoprotein complexes,
since capsid assembly occurs independently in the nucleus. Im-
portantly, CMV capsid genes are highly conserved between
HCMV and animal CMV, and the process of capsid assembly in
HCMV is well studied and defined (63). Additionally, capsid as-
sembly is conserved between alphaherpesviruses (e.g., HSV) and
HCMV (72). GPCMV encodes homologs of the HCMV capsid
genes, and earlier electron microscopy studies demonstrated a
similar icosahedral capsid assembly process in the nucleus as well
as a similar virus maturation process (15, 73). The GPCMV DISC
vaccine strategy was based on a UL85 homolog (GP85) mutant
that was predicted to encode the minor capsid protein (GP85). In
HCMV, UL85 dimerizes with itself and the minor capsid binding
protein (UL46) to form a triplex as part of a fundamental building
block for capsid assembly (63). GPCMV encodes a UL46 homolog
(GP46) which enables triplex formation with GP85. A BLAST
alignment of the predicted GP85 and UL85 nucleotide sequences
demonstrated a high level of sequence conservation between the
open reading frames (56% identity) (Fig. 3). Transient plasmid
expression of the GP85 protein in GPL cells demonstrated that the
protein was located in both the nucleus and cytoplasm (data not
shown). A targeted deletion knockout of the GP85 gene (codons
58 to 241) in a GPCMV BAC resulted in lethal knockout of the
virus, which demonstrated the essential nature of GP85 (data not
shown).
The first stage in the generation of a DISC virus was the devel-
opment of a complementing cell line for virus growth. In the case
of the GPCMV GP85 DISC strain, the classical approach, which
entails use of a cell line that expresses the missing gene in trans, was
replaced by another strategy that employed the Tet-Off Advanced
system, where cells express the transactivator (64). Control of
GP85 gene expression in a recombinant virus was achieved by
placing the gene under the control of the Tet-Off transactivating
protein tTA2 (64). Potentially, this approach has the advantage of
Guinea Pig Cytomegalovirus DISC Vaccine
September 2016 Volume 90 Number 17 jvi.asm.org 7907Journal of Virology
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
placing multiple viral genes under the control of the same Tet-Off
system/Tet-Off transactivating protein and therefore bypasses the
requirement for a cell line expressing the essential target gene(s) in
trans. Establishment of the Tet-Off Advanced system required the
development of a GPL cell line that expressed the Tet-Off trans-
activator tTA2 (Clontech Laboratories). (The procedure for gen-
eration of the GPL Tet-Off cell lines is described in Materials and
Methods.) Overall, 30 potential Tet-Off Advanced cell lines were
isolated and screened for the tTA2 transactivator by transfection
of a luciferase reporter plasmid (Clontech Laboratories) under
TREtight (Tet-Off) promoter control (pTREtightLUC). Expres-
sion of luciferase was assayed by bioluminescence imaging of
transfected plates at 24 h posttransfection. Four cell lines (A4, A20,
A21, and D7) were identified which continued to exhibit consis-
tent levels of tTA2 expression, determined in a luciferase reporter
gene transactivation bioluminescence assay. Figure 4 shows the
results of the transient-expression assays used to screen candidate
cell lines. Plate bioluminescence imaging was employed to ensure
that the assay demonstrated activity across the complete intact
monolayer. Control plasmid transfections (pTREtightLUC and
pTet-Off-Advanced) were performed on GPL cells to provide an
idea of the minimal acceptable level of activity of reporter gene
transactivation. Additionally, pCDNALuc (luciferase under the
HCMV major immediate-early [MIE] protein control) was used
to provide a guide for efficient direct expression of the reporter
gene (Fig. 1). Cell lines A20 and A21 (Fig. 1) were subsequently
used for the propagation of the GP85 DISC mutant virus strain, as
they consistently exhibited the highest levels of reporter gene
transactivation.
In order to generate the GP85 DISC GPCMV mutant, the first-
generation GPCMV BAC was modified at the GP85/GP86 inter-
genic locus. The UTR upstream of theGP85ORF was deleted (Fig.
1) and replaced by partial or complete sequences to generate a
GP85 DISC mutant as described in Materials and Methods, using
specific GP85/GP86 locus shuttle vectors (Fig. 2). Three specific
GP85 GPCMV BAC mutants were generated (Fig. 4). The first
mutant replaced the GP85 UTR sequence (272 bp; coordinates
135907 to 136179) with a Km cassette (designated GP85/GP86Km
GPCMV BAC). The second mutant replaced the UTR with a Km
cassette and SV40 poly(A) sequence downstream of the GP86
coding sequence (designated GP85/GP86Km/poly(A) GPCMV
BAC). The third mutant replaced the GP85 UTR with a Km cas-
sette and SV40 poly(A) sequence and also introduced a TREtight
promoter directly upstream of the GP85 ORF. This third GPCMV
BAC mutant was designated TREGP85 DISC GPCMV BAC. Ver-
ification of the GP85 locus mutations was confirmed by HindIII
restriction profile analysis of wild-type and mutant GPCMV
BACs. Insertion of a Km cassette introduced a novel HindIII site
into the GP85/GP86 locus and disrupted the HindIII A fragment
(approximately 44 kb; GPCMV coordinates 102379 to 146446),
which was modified to produce two novel fragments in the
TREGP85 DISC GPCMV BAC profile of approximately 34.5 kb
and 10.8 kb after inclusion of the extra cassette sequence and de-
letion sequence. Other modifications also produced a similar pat-
tern of the modified HindIII A fragment (Fig. 5). Specific modifi-
cation to theGP85/GP86 locus was also verified by PCR analysis of
the modified locus based on primers used to create the shuttle
vector (left-arm coordinates 134992 to 135906, right-arm coordi-
nates 136180 to 136681). The GP85/GP86 locus and deleted inter-
genic sequence are shown in Fig. 1. Figure 5, panel iv, shows the
FIG3 BLAST alignment of the predicted minor capsid protein (mCP) nucleotide sequence from GPCMV (GP85) and HCMV Towne strain (UL85). (i) Colinear
location of GP85 and UL85 genes in GPCMV and HCMV, respectively. (ii) BLAST search of the GP85 protein identified it as a member of the herpes virus V23
(capsid protein) superfamily. (iii) BLAST (NCBI BLASTp) alignment of GP85 and UL85 proteins. Score, 354 bits (908); E, 2e120; method used, composi-
tional matrix adjust; identities, 172/305 (56%); positives, 226/305 (74%); gaps, 4/305 (1%).
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1.7-kb wild-type locus (GPCMV coordinates 134992 to 136681)
and the 2.5-kb PCR product of the locus with the GP85 5= UTR
deletion and insertion of a 1.1-kb Km cassette. PCR of the
TREGP85 GPCMV BAC GP85/GP86 locus demonstrated a mod-
ified locus of 3.1 kb as a result of the insertion of the Km/SV40
poly(A)/pTREtight cassette and deletion of the original GP85 5=
UTR. Note that the GP85/GP86/Km/poly(A) GPCMV BAC was
correctly modified based on its restriction profile and PCR analy-
ses (data not shown, to limit redundancy).
All three mutant GPCMV BAC clones were transfected onto
both GPL and GPL Tet-Off cell lines as described in Materials and
Methods. Separate transfections of the three GP85 GPCMV BAC
mutants failed to generate infectious virus on GPL cells, and indi-
vidually transfected cells remained GFP positive, but viral plaques
FIG 4 Characterization of GPL Tet-Off cell lines via luciferase reporter gene transactivation. GPL cells (A to D) or candidate GP Tet-Off cells (E to H) were
transfected with a luciferase reporter plasmid under TREtight promoter control (pTREtightLUC). Wells A and C were additionally transfected with the Tet-Off
transactivator (tTA2) expression plasmid. Well B was transfected with a luciferase reporter gene plasmid under HCMV MIE promoter control (pcDNA3LUC).
At 24 h posttransfection, luciferase substrate (D-luciferin) was added, and plates were imaged for 5 min to evaluate bioluminescence (IVIS 50; Xenogen). Shown
are black and white images of six-well plates, with superimposed photon emission intensities. Vertical color bar ranges indicate the highest (red) to lowest
(purple) levels of bioluminescence (in photons per second per square centimeter per steradian) for imaged samples. Tet-Off cell line assays included duplicate
wells for A20 (E and G) and A21 (F and H) cells.
FIG 5 Modification of the GP85 5= UTR in a GPCMV BAC and generation of a DISC GP85 strain BAC. (i) Schematic of the GPCMV genome, with location of
the BAC insertion and HindIII sites indicated. The GP85/GP86 locus is encoded in the HindIII A fragment. (ii) Modifications to the 5= UTR in the GP85/GP86
locus in the wild type (wt; 1) and mutants GP85/GP86KmR BAC (2, top), GP85/GP86KmRpoly(A) BAC (2, bottom), and TRE GP85 (DISC) BAC (3). Also
shown are the approximate sizes of the wild-type and mutant loci, based on the external primer used to generate the originalGP85/GP86 shuttle vector. (iii) EcoRI
restriction profile analysis of wild-type and mutant GPCMV BACs described in panel ii, including wild-type GPCMV BAC (1), GP85/GP86KmR BAC (2), and
TRE GP85 (DISC) BAC (3). The original HindIII A genomic fragment is indicated in blue, and the modified fragment indicated by red dots. (iv) PCR
amplification of the GP85/GP86 locus in wild-type and mutant GPCMV BACs: wild type (1), GP85/GP86 KmR (2), and TRE GP85 DISC (3). The DNA ladder
(measurements in kilobases) was obtained from Invitrogen.
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and virus spread across the monolayer failed to occur (Fig. 6). The
GP85 mutants could be returned to wild type by cotransfection of
the BAC DNA with rescue with the PCR product of the wild-type
GP85/GP86 locus (Fig. 5). Separate transfections of all three GP85
mutant GPCMV BACs onto the GPL Tet-Off cells resulted in vi-
able virus production for the TREGP85 GPCMV BAC, which pro-
duced GFP-positive virus that spread across the monolayer. In
contrast, cells in the other GP85 mutant-transfected wells re-
mained single GFP-positive cells (data not shown). Monolayers
were monitored daily for 3 to 4 weeks with frequent medium
changes. Transfection of each mutant was carried out multiple
times (40) and additional mutants were also tested (data not
shown), but the same result was obtained each time. We con-
cluded that the tTA2 transactivator in the Tet-Off cell line specif-
ically enabled expression of the GP85 gene when under TREtight
promoter control in the TREGP85 GPCMV BAC-derived virus.
Virus stocks of the GP85 DISC virus strain were generated on
Tet-Off GPL cells, and the growth kinetics of the mutant virus on
the complementing Tet-Off GPL cell line were evaluated. The re-
sults in Fig. 7 demonstrate that the DISC virus grew with attenu-
ated growth kinetics on the Tet-Off cell line compared to wild-
type virus, but the normal growth kinetics of the wild-type virus
demonstrated that expression of the Tet-Off transactivator did
not interfere with GPCMV growth. Potentially, the expression
kinetics of the GP85 protein (with the gene under Tet-Off control)
compared to the that for the other triplex components of the UL46
protein (with the gene under GPCMV promoter control) im-
paired the stoichiometry of protein expression to enable optimal
triplex formation. However, an in-depth evaluation of protein
expression would require the development of custom antibodies
to GP85 and GP46 for future Western blot assays. The GP85 DISC
virus was able to successfully infect normal GPL cells as verified by
GFP reporter gene expression in infected GPL cells, but it did not
produce any titratable progeny virus during a 7-day infection of
GPL cells (data not shown). We concluded that the GP85 DISC
strain was restricted to the Tet-Off GPL cells for production of
progeny virus but retained the ability to infect noncomplementing
cells. The GP85 DISC strain expressed an array of viral antigens on
nonsupporting GPL cells which could be detected by Western blot
analysis using hyperimmune sera from convalescent guinea pigs
(data not shown). The immune response to GPCMV was also
evaluated by Western blotting. Figure 8 shows a typical result for
Western blot assays of sera from R1 DISC-vaccinated animals.
Evaluation was carried out in Western blot assays of sucrose-pu-
rified virus as well as GPCMV virus-infected GPL cell lysates (Fig.
8). These results demonstrated that antibodies were generated
against both structural and nonstructural proteins.
Antibody immune response against viral glycoprotein com-
plexes: vaccine regimen 1 (two-shot vaccination) versus vaccine
regimen 2 (three-shot vaccination). Two vaccination regimens
were investigated to evaluate the antibody response to the
GPCMV GP85 DISC vaccine (Fig. 9). In the first vaccine study,
R1, GPCMV-negative female guinea pigs (n 6) were vaccinated
FIG 6 Regeneration of a DISC GP85 GPCMV from GP85 BAC mutants re-
quires a TRE promoter and a cell line expressing a Tet-Off transactivator
(tTA2). (A to C) GP85 mutant GPCMV BACs were individually transfected
into GPL cells: GP85/GP86 KmR (A), GP85/86 KmR poly(A) (B), and TRE
GP85 DISC (C). (D) Mutants were also transfected onto GPL Tet-Off cells.
The TRE GP85 DISC is shown. Individual transfected cells expressed GFP
encoded by the BAC. Virus spread was detected by GFP spread across the cell
monolayer. Images were taken at 16 days posttransfection.
FIG 7 Growth kinetics of DISC GP85 GPCMV versus wild-type GPCMV on
GPL Tet-Off cells. GPL Tet-Off cells were infected at a multiplicity of infection
of 1 PFU/cell with each respective virus in separate wells of six-well dishes.
Samples were taken on different days postinfection and titrated in duplicate as
previously described (33). Results are plotted as the virus titer versus day
postinfection.
FIG 8 Western blots of wild-type GPCMV. GPCMV (purified virus particles
or total cell lysate) were separated by SDS-PAGE and immunoblotted with
anti-GPCMV sera (1:2,000 dilution) from DISC-vaccinated animals and with
anti-guinea pig IgG–HRP (1:500; Sigma) as described in Materials and Meth-
ods. (A) Sucrose-purified GPCMV. (B) GPCMV-infected GPL cell lysate. MI,
control lanes with uninfected GPL cells. Protein sizes are indicated in kilodal-
tons (Bio-Rad ladder).
Choi et al.
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subcutaneously with 103 PFU DISC virus and subsequently
boosted 4 weeks post-initial infection with an equivalent dose.
Sera collected 4 weeks postbooster (8 weeks post-initial infection)
were tested for GPCMV seroconversion and the level of neutral-
izing antibodies. All animals seroconverted and showed relatively
high anti-GPCMV ELISA titers (1:1,280 to 1:5,120; mean,
1:2,987), but this was lower than the result with pooled hyperim-
mune animal sera convalescent for wild-type GPCMV infection
(mean titer, 1:5,000). The immune responses to specific glycopro-
teins (gB, gH/gL, and gM/gN) were also evaluated for DISC-vac-
cinated animals by using newly developed ELISAs (36). ELISA
titers of the DISC-vaccinated animals for anti-gB were not as ro-
bust as those for wild-type GPCMV hyperimmune sera (1:640
versus 1:1,600; P 	 0.05). Similarly, the glycoprotein complex
gH/gL titer was lower (1:216 versus 1:960; P 	 0.05) (Fig. 10A).
However, the immune response of DISC-vaccinated animals to
the gM/gN complex was slightly stronger than, but not statistically
significant, the response to hyperimmune sera (1:704 versus
1:480). The neutralizing antibody titer of DISC-vaccinated ani-
mals on GPL cells was lower, 1:960 (P 	 0.05) than seen with a
1:4,200 dilution of hyperimmune sera (Fig. 10B).
In the second vaccine study, regimen 2, GPCMV-negative fe-
male guinea pigs (n 5) were vaccinated subcutaneously with 103
PFU DISC virus and subsequently received equivalent booster in-
oculations of 103 DISC virus at 4 and 8 weeks post-initial inocu-
lation (Fig. 9). Sera collected 4 weeks post-second boost (12 weeks
post-initial vaccination) were tested for anti-GPCMV titers and
the specific immune response to glycoprotein complexes, as de-
scribed for R1 samples. The additional DISC vaccination in R2
animals appeared to enhance the immune response to GPCMV.
The anti-GPCMV ELISA titers ranged from 1:2,560 to 1:10,240,
with a mean titer of 1:5,120, resembling titers for hyperimmune
GPCMV animals (Fig. 10A). Specific glycoprotein complex ELISA
results demonstrated an increase in the immune response to both
gB (1:3,000 titer, versus hyperimmune titer of 1:1,600) and gH/gL
(1:2,700 titer versus 1:960 in hyperimmune group; P	 0.05). The
antibody titer against gM/gN also increased (1:4,000 versus hyper-
immune titer of 1:480;P	 0.05). Although the R2 booster strategy
increased the immune response to all specific complexes tested,
the impact on the gM/gN immune response was relatively un-
usual, as titer levels were above those of hyperimmune animals.
The reason for this dramatic change in the gM/gN immune re-
sponse is undetermined at this time and is worthy of further in-
vestigation. It should be noted that although our vaccine studies
compared the immune response with that in hyperimmune ani-
mals, the actual immune response to the GPCMV glycoprotein
complexes as well as the anti-GPCMV titers are more varied and
lower in naturally infected animals, based on results obtained
from GPCMV-positive animals purchased from various animal
vendors (data not shown).
Overall, the DISC vaccine strategy in vaccinated animals was
more successful with a two-booster approach (R2) rather than the
single-booster approach (R1). In the R2 study, the anti-GPCMV
titers increased and, importantly, the antibody responses for the
specific glycoprotein complexes were also increased compared to
those in R1. However, despite improved values in the R2 study
with titers equivalent to or better than those for the hyperimmune
sera, the neutralizing titers for animals in the R2 study were below
those for hyperimmune sera (1:2,000 versus 1:4,200; P 	 0.05)
(Fig. 10B) and only slightly higher than in the R1 study. Poten-
tially, a missing component of the immune response in DISC-
vaccinated animals compared to wild-type virus-infected animals
was an immune response to the homologous pentameric complex
(58), as the DISC vaccine was based on a lab-adapted virus that lacked
a full-length UL128-131 homologous locus (15, 26). The immune
response to the homologous pentameric complex is under investiga-
tion in our laboratory via the use of attenuated GPCMV mutants as
well as a second-generation GPCMV DISC vaccine.
T cell immune response to the pp65 homolog protein. The T
cell response to the DISC virus vaccine was evaluated in a newly
FIG 9 Overview of DISC GP85 vaccination schedules and the preconception vaccine study. (a and b) In the initial characterization of the immune response to
the DISC vaccine, two vaccine regimens were employed: R1 (a) and R2 (b). DISC virus inoculations are indicated with the arrow along with a virus symbol.
Animals were bled for immune response measurements at the indicated weeks post-initial vaccination. Animals were euthanized at the end of the vaccination
schedule (and after confirmation of seroconversion) to determine the T cell response via an ELISPOT assay as described in Materials and Methods. (c)
Preconception vaccine study (group 1) following vaccine regimen R1. During the late second trimester of pregnancy, animals were challenged with wild-type
GPCMV (105 PFU) and then allowed to go to term. (d) Control nonvaccinated animals (group 2) from the congenital vaccine study.
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developed guinea pig-specific IFN- ELISPOT assay as described
in Materials and Methods. Pools of 9-mer peptides designed to
target the CD8T cell response were used to pulse isolated spleno-
cytes from animals in the R1 and R2 study groups as well as wild-
type GPCMV-infected animals. The peptide pool matrix was de-
signed to optimally utilize the largest number of peptides in the
most efficient and cost-effective manner (69, 70). The GP83 pro-
tein has a predicted length of 565 amino acids, which generate 140
overlapping 9-mer peptides. This enabled 24 pools of peptides in a
12-by-12 square matrix, with each peptide appearing in two pools.
The intersection of positive pools identified the stimulating pep-
tides, narrowing the potential candidate peptides that could be
tested individually. The concentration of peptide pools used was
determined by testing different concentrations based on HCMV
IFN- ELISPOT results (74, 75). For the GP83 peptide pools, a
final concentration of 5 g/ml gave the highest stimulation of
IFN--producing cells. ConA (positive control) produced an av-
erage of 5,840 SFC per 106 stimulated cells (
 235 [standard de-
viation]). Unstimulated cells (634 
 5.8 SFC/106 cells) and
DMSO-stimulated cells (548
 16 SFC/106 cells) produced simi-
lar results, which were used to establish the baseline background
level. Each animal’s response to GP83 peptide stimulation was
slightly different, but at least 50% of the animals responded to
peptide pools V, VIII, X, and XX (data not shown). An increase in
IFN--secreting cells in response to peptide pools X and XX oc-
curred in all animals. Spot-forming cells from group R1 animals
responding to pool X (2,621 
 508 SFC/106 cells) or pool XX
(2,227
 590 SFC/106 cells) were similar to those seen in wild-type
GPCMV-infected cells stimulated with pool X (2,900
 468 SFC/
106 cells) and pool XX (3,220 
 1,362 SFC/106 cells). Further-
more, there were no significant differences in responses to pool X
(3,220 
 1,114 SFC/106 cells) or pool XX (2,918 
 990 SFC/106
cells) in group R2 (Fig. 11), despite a higher humoral response to
GPCMV antigens. Certain GP83 peptide pools (pools II and IV)
failed to routinely stimulate the splenocytes above background
levels in infected animals (Fig. 11).
Overall, the DISC vaccine was confirmed to induce a T cell
response against the pp65 homologous protein, which is consid-
ered a major T cell target with HCMV. Encouragingly, the DISC
vaccine T cell response was similar to that in animals challenged
with wild-type live virus. An analysis of the immune response in
naturally infected animals remains to be investigated to determine
if there is a difference in response in vaccinated or hyperimmune
animals. The stimulation of splenocytes from DISC-vaccinated
animals by GP83 peptide pools allowed the identification of a hot
spot region within the GP83 protein, which will enable a narrower
range of peptides to be used in future studies and enable identifi-
FIG 10 Antibody immune responses (determined in ELISAs) to GPCMV and
specific viral glycoprotein complexes (gB, gH/gL, and gM/gN) in DISC GP85-
vaccinated guinea pigs. (A) Immune responses of animals vaccinated with
DISC GP85 under the R1 or R2 regimen were compared to animals hyperim-
munized with wild-type GPCMV. Results shown are means for each group
with standard deviations represented by error bars. Statistically significant
differences (P	 0.05; Mann-Whitney test) are shown by lowercase italic letters
for comparisons as follows: a, hyperimmune versus R1; b, R1 versus R2; c,
hyperimmune versus R2. (B) Neutralizing antibody titers on fibroblast cells
from hyperimmune sera, compared to those from the R1 and R2 regimens.
Statistically significant differences (P 	 0.05; Mann-Whitney test) are indi-
cated by lowercase italic letters for comparisons as follows: d, hyperimmune
versus R1; e, hyperimmune versus R2.
FIG 11 Evaluation of animal T cell response to the GPCMV vaccine. Gamma
interferon ELISPOT assay results are shown for splenocyte responses to
GPCMV GP83 peptide pools in R1 or R2 vaccinated and wild-type (wt)
GPCMV-infected animals. The assays were carried out as described in Mate-
rials and Methods, with splenocytes isolated from DISC GP85-vaccinated an-
imals (vaccine regimens R1 and R2) or wild-type GPCMV-infected animals.
Overlapping peptides (9-mers) spanning the complete GP83 protein sequence
were assigned to 24 peptide pools (I to XXIV). Results are shown for selected
GP83 peptide pools: II, IV, X, and XX. ConA was used as a positive control, and
negative controls included unstimulated and DMSO-treated cells. Final
counts were calculated based on SFC per 106 cells after background spots (cells
only, without any stimulation) were subtracted. GP83 peptide pools X and XX
produced highly stimulated cells, whereas pools II and IV resulted in poorly
stimulated cells.
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cation of the most reactive T cell epitope. However, the use of
outbred Harley guinea pigs in future studies may have to be
changed to the use of inbred strain 2 animals to limit animal-to-
animal variation in the GP83 T cell response.
Congenital GPCMV protection study (2-shot vaccination,
regimen 1). Previous sections described how the DISC vaccine
strategy induced effective antibody and T cell responses against
GPCMV in vaccinated animals. Consequently, the DISC virus
vaccine strategy was evaluated for the ability to protect against
congenital GPCMV infection under vaccine regimen 1 (Fig. 9).
Initially, 29 female guinea pigs seronegative for GPCMV were ran-
domly assigned into two groups: group 1, vaccinated (DISM; n
14); and group 2, control unvaccinated (NOD; n 15). Group 1
animals were vaccinated with 103 PFU subcutaneously with the
GP85 DISC virus, and 1 month postvaccination the animals re-
ceived an equivalent booster dose of the DISC strain. Evaluation
of their serum status revealed that the animals had a similar range
of mixed anti-GPCMV ELISA titers, which ranged from 1:160 to
1:2,560, and neutralizing antibody titers as the animals from the
R1 study (data not shown). Once animals were confirmed to have
an immune response to the DISC vaccine, they were paired with
seronegative male guinea pigs for mating. Control group 2 (non-
vaccinated animals) were also paired for mating at this time with
seronegative males. Dams were confirmed pregnant by palpation
(at 20 to 25 days of gestation). At approximately late second tri-
mester, dams were challenged subcutaneously with 105 PFU of
wild-type salivary gland stock virus, and animals were allowed to
go to term. The viral loads in target organs (liver, lung, spleen, and
brain) of live or stillborn pups were evaluated by real-time PCR.
Table 2 summarizes the pregnancy outcomes in the two animal
groups. Overall, more dams carried pregnancy to term in the vac-
cinated group (100% versus 69.2%), which also had a higher pro-
portion of live pups (94.1% versus 63.6%). Additionally, the
DISM group had a greater overall number of live pups (48 versus
28). Although there were 3 dead pups in the vaccinated animal
group, all of these pups were determined to be negative for
GPCMV and death was attributed to a complication of pregnancy.
In contrast, all 16 stillborn pups in the control nonvaccinated
group were positive for GPCMV, with 80% of tissue analyzed
(liver, lung, spleen, or brain) positive for GPCMV. Additionally,
in the nonvaccinated group, two litters were reabsorbed by the
dam. Based on the outcome (live versus stillborn pups) between
groups, the DISC vaccine was considered effective in protecting
against congenital CMV mortality (P  0.0002, based on live
births of 94.1% versus 63.6%). In this study, the CMV mortality
rate in the control group was 36.4% based on dead pups for term
litters. This excluded 2 litters reabsorbed by the dams in the con-
trol group. In previously published congenital GPCMV infection
studies, with a challenge virus dose of 105 PFU the mortality rate
ranged from 34 to 81% (51, 61, 76–80). The results of the present
study fall within this range. However, in previous studies the
higher mortality rates included animals that aborted within 2
weeks of virus challenge. This scenario did not occur in our stud-
ies, but reabsorbed litters were excluded from the present study,
which could have increased the reported mortality rate.
Based on pup tissue positive for GPCMV, a transmission rate
of 75.9% for the control group was reduced to 23.5% in the vac-
cine group (P  0.0001). The transmission rate in the control
group was roughly similar to the congenital GPCMV transmission
rate observed for control nonvaccinated groups in other pub-
lished studies that used challenge virus at a dose of 105 PFU. In
previous studies, the GPCMV transmission rate ranged from 50 to
85%, with the majority in the range of 65 to 85% (average rate,
74.4%) (51, 76–80). In one study with a virus challenge dose of 106
PFU, the transmission rate was 70% (81), which indicated that a
higher dose of challenge virus does not necessarily result in a
higher transmission rate. Analysis of viral loads in pup tissues
from both groups demonstrated that the tissues from the control
nonvaccinated group had a higher frequency of GPCMV-positive
tissue (Table 3). A 52.4% reduction in GPCMV transmission in
the vaccinated group (23.5% transmission) compared to the con-
trol group (75.9% transmission) indicated that the DISC vaccine
strategy was more effective than levels reported for studies with
live GPCMV vaccine strains (78, 80) or gB-based vaccine strate-
gies (76, 77, 79, 82). A comparison of the outcome of our study
versus those of previous GPCMV vaccine studies is covered in
more detail in the Discussion.
The majority of pup tissues in the vaccinated group were neg-
ative for virus, but a lower number of pups were positive. How-
ever, while the viral loads in target tissues of these individual pos-
itive pups were lower than those found in comparable tissues of
the nonvaccinated group, the differences were not statistically sig-
TABLE 2 Congenital infection outcomes for live versus dead pupsa
Treatment group (n)
Litter outcomes
Outcomes for total pups (no.
[%])
Total Live only Dead only Mixed Reabsorbed Live borna Stillborn
DISM (14) 13 11 0 2 0 48* (94.1) 3 (5.9)
NOD controls (15) 13 8 4 1 2 28* (63.6) 16 (36.4)
a DISM, DISC-vaccinated mothers. *, P 0.0002 compared to controls (Fisher’s exact test).
TABLE 3 Impact of DISC vaccine on GPCMV transmission, based on frequencies of GPCMV-positive pups in each specific tissue group
Vaccine group (n)
No. (%) of pups positive for GPCMV in specific tissue [P value]a
No. (%) of CMV
pupsb [P value]Lung Liver Spleen Brain
DISM (51) 7 (13.7) [0.0001] 2 (3.9) [0.0013] 2 (3.9) [0.0001] 5 (9.8) [0.0006] 12 (23.5)[0.0001]
NOD controls (29) 17 (58.62) 9 (31.03) 19 (65.52) 13 (44.83) 22 (75.9)
a P values are based on comparisons using Fisher’s exact test of the number of animals CMV for the specific organ in the vaccinated group versus the NOD control group.
b Number (percentage) of pups in which GPCMV was detected in at least one organ.
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nificant except for the brain (Table 4). An important benchmark
for the vaccine strategy was the prevention of CMV infection in
pup brains. Consequently, although the vaccine strategy was suc-
cessful in reducing congenital infection, the approach failed to
completely prevent viral infection of pup brains, with 5/51 posi-
tive for a low level of virus. In the nonvaccinated group, 13/29
pups had brain infection, and the viral loads were higher than in
the DISM group (Table 4) (P 0.05).
The congenital transmission rate from dams with an anti-
GPCMV titer of 1:640 or less was 32.4%, compared to 5.9% (P
0.042) for dams with an anti-GPCMV titer of 1:1,280 or greater
(Table 5). Interestingly, a comparative analysis of individual ani-
mal anti-GPCMV antibody titers with congenital CMV transmis-
sion demonstrated that a high anti-GPCMV ELISA titer was not
necessarily a predictor for protection against congenital infection.
However, the incidence of congenital CMV infection in the high-
titer group was significantly lower. If anti-GPCMV ELISA titers
were grouped into low (1:160), medium (1:320 to 1:640), and high
(1:1,280 to 1:2,560) categories, then congenital infection occurred
across all groups, as follows: low titer (2 pups); medium titer (9
pups); high titer (1 pup) (Table 6). Potentially, an additional
booster vaccination could have induced a stronger immune re-
sponse, as indicated with DISC vaccine R2 studies. However, the
rationale for testing efficacy with the R1 vaccination strategy was
to match previous recombinant vaccine studies that used live at-
tenuated GPCMV strains (78, 80, 81, 83). The outcome in com-
parison to previous GPCMV vaccine studies is covered in more
detail in the Discussion. Overall, the DISC vaccine strategy was
effective in reducing congenital infection compared to the re-
sponse in the control group. Additionally, the DISC vaccine was
more effective than described in previously published studies for
most of the attenuated live GPCMV vaccines.
DISCUSSION
Vaccines strategies against congenital CMV that have gone for-
ward to human clinical trials have mainly focused on a single
target antigen (e.g., gB glycoprotein) and neutralizing antibodies.
However, these strategies have at best provided 50% efficacy (41).
Potentially, a vaccine against congenital CMV has to induce both
an antibody to key neutralizing glycoprotein complexes that are
essential for virus entry and additionally target important T cell
target antigens to provide a comprehensive protective immune
response against CMV. It is unlikely that a subunit vaccine or a
recombinant vector delivery system (e.g., modified vaccinia virus
Ankara [MVA]) could deliver such a complicated array of anti-
gens and successfully evoke an immune response equivalent to
that in CMV convalescent patients. An attenuated live recombi-
nant CMV vaccine strategy is potentially an effective approach,
since it mimics a natural infection and in theory induces an im-
mune response equivalent to convalescent CMV immunity. How-
ever, attenuation covers a wide spectrum of viral mutants, and
potentially some or all attenuated live vaccine strains have a safety
risk associated with them, especially if the virus is able to establish
latency in the host and contribute to disease later in life. A poten-
tially safer CMV vaccine strategy entails the use of a non-replica-
tion-competent virus. This approach was investigated for guinea
pig CMV infection, and the term DISC virus was adopted for the
type of virus vaccine studied. The term DISC vaccine (defective
infectious single-cycle vaccine) describes accurately an important
feature of our vaccine strategy. The recombinant virus lacked the
ability to express an essential gene (GP85, encoding the small cap-
sid protein), and as such the virus could infect cells but lacked the
ability to make progeny virus because of a defect in capsid assem-
bly. Consequently, the DISC virus stock could only be propagated
on a complementing cell line. The term DISC virus was originally
used to describe an HSV-1 vaccine strategy, where the gH glyco-
protein had been knocked out and the gH protein was supplied in
trans in a complementing cell line (71). The DISC GPCMV ap-
proach deviated from this original strategy for HSV, as the gH
glycoprotein in GPCMV was considered highly important for the
generation of target antigen complexes (36). A capsid mutant was
deemed more suitable, as capsid proteins are essential for the gen-
eration of progeny virus but in themselves are relatively unim-
portant target antigens for CMV. However, a rhesus CMV (Rh-
CMV) gH knockout mutant virus was generated (84) and is under
investigation for use as a CMV vaccine in rhesus macaques. In an
additional further development for the DISC vaccine strategy, the
essential capsid gene was not expressed by a complementing cell
TABLE 4 Congenital infection outcome, based on viral load in target
tissues of pups
Treatment
group
Viral load in target tissue (mean
 SD) [P value]a
Lung Liver Spleen Brain
DISM 2.5
 2 2.1
 1.7 2.2
 1.5 2.9
 2.6
NOD 2.6
 2 2.6
 2.1 3.2
 2.9 3.3
 2.7
P value [NSb,c] [NSb] [NSb] [0.05c]
a Viral loads are expressed as log10 genome copies per milligram of tissue. P values are
shown within brackets; NS, not significant (P 0.05).
b P value derived via Student’s t test.
c P value derived via Mann-Whitney test.
TABLE 5 Congenital CMV infection outcomes in relation to anti-
GPCMV titers
Anti-GPCMV titer group
No. of live pups/
no. of dead pups
No. of CMV pups/
total pupsa (%)
Low to mid-range (1:160–1:640) 33/1 11/34* (32.4%)
High (1:1280–1:2,560) 15/2 1/17* (5.9%)
a The “total pups” includes live pups and dead pups. *, P 0.042 (Fisher’s exact test).
TABLE 6 Individual congenital CMV infection outcomes in relation to
anti-GPCMV titers
DISC-vaccinated
mother no.
Anti-GPCMV titer
(titer group)a
Pups (no. live/
no. dead)
No. of CMV
pups
DISM11 1:160 (L) 3/0 2
DISM12 1:160 (L) 5/0 0
DISM6 1:320 (M) 1/0 0
DISM14 1:320 (M) 4/0 4
DISM1 1:640 (M) 3/0 0
DISM3 1:640 (M) 5/0 0
DISM5 1:640 (M) 4/0 2
DISM7 1:640 (M) 4/0 1
DISM10 1:640 (M) 4/1 2
DISM2 1:1,280 (H) 3/0 0
DISM9 1:1,280 (H) 4/0 0
DISM13 1:1,280 (H) 3/2 1
DISM8 1:2,560 (H) 5/0 0
a Anti-GPCMV titer ranges were grouped as follows: L, low (1:160); M, mid-range
(1:320 –1:640); H, high (1:1,280).
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line in trans. Instead, the Tet-Off Advanced system was intro-
duced into guinea pig fibroblast cells to enable generation of a
complementing cell line. This also required modifying the GP85
gene in GPCMV to place gene expression under the control of the
Tet-Off transactivator (tTA2) to enable GP85 DISC virus mutant
growth on the Tet-Off cell line. This approach potentially enabled
the development of next-generation DISC virus strains with addi-
tional mutations (e.g., pp71 expression) under Tet-Off promoter
control with a single controlling complementing cell line. In mu-
rine CMV (MCMV), a spread-deficient virus vaccine strategy was
investigated using an M94 mutant virus. In this study, a reverse
strategy was used that incorporated the Tet-On transactivator into
the recombinant virus, which also carried an M94 knockout. The
complementing cell line encoded the M94 gene, which was in-
duced by transactivator expression during MCMV infection. A
similar strategy could have been employed for the GPCMV GP85
mutant, especially since a GP85 deletion mutant was also gener-
ated as part of the initial study. A potential downside of this ap-
proach would have been viral expression of the transactivator in
the host animal. However, the M94 mutant vaccine strategy was
safe even in innate immune response knockout mice and highly
protective against challenge with a pathogenic strain of MCMV
because of an induced T cell response (CD4 and CD8) as well as
effective neutralizing antibodies (85).
In the GPCMV study, a newly developed gamma interferon
ELISPOT assay demonstrated that the GP85 DISC vaccine evoked
a T cell response to the homolog pp65 protein (GP83). Specific
regions within the GP83 protein were identified that produced a
heightened response. Additional studies are required to better de-
fine if the GP83 response is mainly CD4 or CD8 based. A pre-
vious GPCMV study demonstrated that the GP83 antigen was
partially protective against congenital CMV infection. This previ-
ous study employed a defective alphavirus system that encoded
GP83, and both CD4 and CD8 responses were induced, as
shown by flow cytometry (61). Mouse monoclonal antibodies to
guinea pig CD3, CD4, and CD8 markers are available (86), and so
further characterization of the T cell response to GP83 is possible.
However, an evaluation of the T cell response to other homolo-
gous T cell target antigens (e.g., IE1 and IE2) is also a high priority
for future studies with GPCMV. Currently, splenocytes are neces-
sary to perform this new guinea pig ELISPOT assay. Therefore, it
was not possible to correlate the level of T cell response to the pp65
antigen and protection against congenital infection, since animals
were required to carry their pregnancy to term, at which point the
challenge virus would have complicated the results for any
ELISPOT assay. Consequently, this aspect could not be evaluated
for the congenital vaccine study but remains an important aspect
that in this study is only partially defined.
Both mouse and rhesus macaque CMV animal model studies
have demonstrated the importance of a T cell response to the virus
to prevent virus dissemination, and vaccine studies suggest that
other target antigens in addition to pp65 are important targets (87,
88). However, in the context of congenital CMV infection, the lack
of an MCMV congenital infection model prevents any evaluation.
Technical issues and additional expense have limited the number
of RhCMV studies, but a recent congenital RhCMV study sug-
gested that a CD4 response does have a controlling role in protec-
tion against congenital CMV infection but that the effect impacts
both CD8 cells and the antibody response (89).
It is likely that an important component of protection against
congenital CMV infection is neutralizing antibodies directed to
critical viral complexes necessary for cell entry. Importantly, an-
tibodies can cross the placenta, and therefore anti-CMV antibod-
ies can function in both the maternal and fetal compartments
(90). In an earlier study, we characterized the GPCMV gH/gL/gO
and gM/gN homologous glycoprotein complexes and demon-
strated their essential nature and their importance as immune
targets via newly developed ELISAs (36). Overall, the DISC vac-
cine strategy generated a high anti-GPCMV antibody titer, and the
vaccine regimen with 2 booster shots resulted in an antibody re-
sponse similar to that of natural immunity in hyperimmunized
animals. The DISC vaccine induced antibody responses to gB and
gH/gL, with similar titers as those found in animals convalescent
for natural infection, whereas the immune response to the gM/gN
complex was weaker against natural infection. The neutralizing
antibody titer was on average lower than that seen in convalescent
animals. Unfortunately, other current GPCMV vaccine studies
have not included advanced glycoprotein-specific ELISAs, and
therefore it is difficult to evaluate previous reports alongside this
current research. Recent studies based on live attenuated GPCMV
vaccines have demonstrated a robust anti-GPCMV antibody titer
and a specific immune response to gB based on Western blot anal-
ysis. In our present study, two vaccine regimens were explored for
the DISC virus in guinea pigs, and it appeared that a two-booster
strategy dramatically increased the immune response to the DISC
virus compared to a single-booster strategy. A two-booster DISC
vaccine strategy induced an antibody response comparable to that
seen for live attenuated GPCMV (anti-GPCMV and gB titers), and
a single-booster DISC strategy resulted in lower titers. In contrast,
GPCMV gB-specific vaccine strategies produced antibody titers
higher than seen for natural convalescent immunity (51, 77, 79,
91), but these gB vaccine strategies were less successful in protect-
ing against congenital infection than was the DISC vaccine. The
most effective gB-based vaccine strategies reduced transmission
rates from 82 to 45% (gB recombinant baculovirus/GSK adju-
vant), 77 to 41% (gB DNA vaccine), and 79 to 59% (MVA gB) (76,
77, 79). Potentially, a failing of these gB vaccine strategies was that
the gB lacked a C-terminal domain and therefore there was an
inability of the recombinant gB to multimerize, as seen in natural
infection. Consequently, a large amount of the gB immune re-
sponse was potentially directed to the linear, homologous AD-1
domain (92) rather than other gB antigen targets. However, a
more recent study by Cardin et al. (82), which used a recombinant
lymphocytic choriomeningitis virus vector that encoded gB with a
C-terminal domain but lacked a transmembrane domain, did not
increase protection against transmission (reduced from 83% to
60%) despite generation of high titers of antibody to gB.
Previous congenital vaccine studies based on live attenuated
GPCMV included an RNA-dependent protein kinase (PKR) mu-
tant virus (78), a major histocompatibility complex class I-down-
regulated mutant (80), and a GP83 knockout strain (81). The
vaccine strategies were able to reduce transmission by various lev-
els: from 65% to 33% (78), 83% to 57% (80), and 70% to 17%
(81), respectively. Surprisingly, the pp65 homolog (GP83) knock-
out mutant appears to be the most effective live vaccine strategy
despite a previous vaccine strategy that used a defective alphavirus
encoding GP83 and demonstrated the importance of the T cell
response to GP83 in protecting against congenital infection
(transmission reduced from 85% to 47%) (61). Currently, only
the GP83 knockout mutant vaccine strategy is more effective than
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September 2016 Volume 90 Number 17 jvi.asm.org 7915Journal of Virology
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
the DISC vaccine in reducing the congenital transmission rate.
However, theGP83mutant virus has near-normal growth kinetics
in tissue culture, as does an HCMV pp65 mutant (30, 93). Conse-
quently, a live HCMV vaccine based on a pp65 knockout might
present an unacceptable risk compared to a DISC vaccine strategy,
which would have a greater safety factor due to the DISC virus’s
inability to replicate outside the supporting cell line.
Unfortunately, the more-effective DISC vaccine regimen was
evaluated after the congenital vaccine protection study had been
initiated with a single vaccine booster approach. Nonetheless, the
DISC vaccine was highly effective in protecting against congenital
CMV infection, and importantly, high anti-GPCMV titers were
not necessarily an indicator of effective protection against congen-
ital infection. As noted above, it is likely that the T cell response to
various target antigens was also important in the prevention of
congenital infection in the setting of the current vaccine, and the
immune response to the GP83 was an indicator of a positive T cell
response to the DISC vaccine. However, a key component missing
from the current DISC vaccine was the homologous pentameric
complex. Clinical strains of HCMV, unlike lab-adapted strains,
encode a pentameric glycoprotein complex (gH/gL/UL128-130-
131) for virus entry into epithelial and endothelial cells via an
alternative endocytic pathway of cell entry rather than a gB- plus
gH/gL-mediated cell membrane fusion approach (94–99). The
pentameric complex is considered an important neutralizing tar-
get for HCMV on epithelial/endothelial cells and presumably for
congenital infection, given the epithelial/endothelial structure of
the placenta. The importance of the endocytic pathway in virus
infection of cells is underscored by the fact that a gB subunit
HCMV vaccine, despite generating a high-titer neutralizing im-
mune response on fibroblasts, lacks an effective ability to neutral-
ize infection of endothelial and epithelial cells compared to con-
valescent-phase sera (41, 52–55). With RhCMV, the pentameric
complex has been demonstrated to be an important pathogenicity
factor as well as a neutralizing target antigen (100, 101). In
GPCMV, a homologous UL128-131 locus has been identified, and
the ability to form a pentameric complex has been investigated
(28, 58). We recently demonstrated that this complex is important
for virus tropism to epithelial cells, pathogenicity, and congenital
infection (103). Importantly, the homolog pentameric com-
plex is highly immunogenic (102). Virus serially passaged as sali-
vary gland stock in animals is stably maintained, but virus on
fibroblast cells rapidly undergoes mutations or deletions in this
region. Our current DISC vaccine strategy is based on a first-
generation GPCMV BAC which carries a deletion in the homol-
ogous UL128-131 locus (15, 26). Consequently, the DISC vaccine
is incapable of generating an immune response to the pentameric
complex, which is potentially an important component of the
immune response to GPCMV in convalescent animals. Impor-
tantly, we recently identified the pentameric complex as an impor-
tant target for neutralization of virus infection of epithelial cells
(102). Therefore, introduction of the pentameric complex in a
second-generation DISC vaccine is likely to have a significant im-
pact on the efficacy of a future DISC vaccine for congenital CMV
protection. It is important to note that none of the live GPCMV
attenuated vaccine strategies evaluated to date have included a
viable pentameric complex; modification of these strains could
potentially enhance the efficacy of these vaccine strategies. Indeed,
a new GP83 knockout mutant virus that also encodes a pentam-
eric complex was highly effective in inducing a robust immune
response and reducing congenital transmission (102).
In conclusion, the first-generation DISC vaccine against con-
genital GPCMV is a safer strategy than the use of a live attenuated
virus, as the new vaccine lacks the ability to produce progeny virus
and disseminate in the host. Importantly, the virus evokes an im-
mune response similar to natural infection, which includes an
antibody response to viral glycoprotein complexes necessary for
cell entry and a T cell response to the pp65 homolog. The vaccine
strategy was successful in fully preventing pup deaths and greatly
reduced the level and incidence of pups with congenital CMV
infection compared to a nonvaccinated control group. This prom-
ising vaccine strategy presents potential opportunities for im-
provement via the inclusion of the homolog pentameric complex,
which is considered an important complex for virus infection of
epithelial cells (103) and a variety of other cell types. The potential
addition of neutralizing antibodies to this complex will greatly
reduce congenital transmission.
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